What's Happening?
MTF Biologics has appointed New Horizon Medical Solutions (NHMS) as the exclusive distributor of its AmnioBand Membrane to U.S. wound care specialists, podiatrists, and mobile care practitioners. This partnership aims to enhance access to AmnioBand, a placental
allograft product supported by Level 1 clinical evidence. NHMS's specialized provider network and field support will facilitate consistent allograft access and expert point-of-care support. The agreement underscores MTF Biologics' commitment to expanding patient access to evidence-supported tissue solutions and NHMS's focus on equipping wound care providers with the necessary clinical tools.
Why It's Important?
The distribution agreement between MTF Biologics and NHMS is significant for the wound care industry, as it ensures broader access to a clinically validated tissue solution. AmnioBand's availability through NHMS's network can improve treatment outcomes for patients with chronic wounds, surgical reconstruction needs, and other conditions. The partnership also highlights the importance of collaboration between medical product developers and specialized distributors in addressing complex healthcare challenges. By providing reliable access to high-quality products, this agreement supports clinicians in delivering effective and efficient care.
What's Next?
As the exclusive distributor of AmnioBand, NHMS will focus on integrating the product into its existing wound care model, leveraging its clinical field teams and provider relationships. MTF Biologics may continue to explore additional partnerships to expand the reach of its tissue solutions. The success of this distribution model could lead to further innovations in wound care and the development of new products that address unmet clinical needs. Ongoing research and clinical trials will be essential in validating the efficacy of AmnioBand and other similar products in diverse healthcare settings.
